Effect of Vitamin C on mortality of critically ill patients with severe pneumonia in intensive care unit: a preliminary study

Table 1 Demographic characteristics of patients

Variable		Control	Intervention	P value
Age (Years)		58.25 ± 13.1	56.93 ± 12.3	0.47
Male/Female		22/16	24/18	0.39
APACHE		22.7 ± 4.26	24.5 ± 5.35	0.57
SOFA		10.7 ± 2.70	12.54 ± 2.65	< 0.001
Pneumonia				0.56
VAP		12	13
CAP		10	11
HAP		18	16
PSI		188.52 ± 52 ± 33.87	194.72 ± 29.83	0.38
CURB-65		3.55 ± 0.71	3.72 ± 0.67	0.26
MV duration (day)		8.92 ± 2.96	4.05 ± 2.29	< 0.001
ICU LOS (day)		14.15 ± 3.12	12.77 ± 3.71	0.07
Vasopressor use (day)		3.39 ± 1,23	2.28 ± 1.24	0.003
Vasopressor dose (microg/min)		8.26 ± 3.58	6.8 ± 3.18	0.14
Need to mechanical ventilation^α		9	5	0.24
Mortality		11	6	0.17
Comorbidities^a	AKI	22(55%)	16(40%)	P = 0.144 X2 = 6.763
	DM	11(27.5%)	25(62.5%)
	Cardiovascular	13(32.5%)	18(45%)
	Cerebrovascular	8(20%)	11(27.5%)
	Malignancy	5(12.5%)	3(7.5%)

APAHE acute physiology and chronic health evaluation SOFA sequential organ failure assessment VAP ventilator associate pneumonia CAP community acquired pneumonia HAP hospital acquired pneumonia PSI pulmonary severity index CURB-65 (confusion, blood urea > 42,8 mg/dl, respiratory rate > 30/min, blood pressure < 90/60 mmHg, age > 65)
^aSee chart 1

ISSN: 1471-2334